Objective
Infantile-onset spinal muscular atrophy (SMA) is the most common
genetic cause of infant mortality, typically resulting in death prior to age
2. Clinical trials in this population require an understanding of disease
progression and identification of meaningful biomarkers to hasten
therapeutic development and predict outcomes.
Methods
A longitudinal, multi-center, prospective natural history study
enrolled 26 SMA infants, and 27 control infants less than six months of age.
Recruitment occurred at 14 centers over 21 months within the NINDS-sponsored
NeuroNEXT Network. Infant motor function scales (TIMPSI, CHOP-INTEND and
AIMS) and putative physiologic and molecular biomarkers were assessed prior
to 6 months of age and at 6, 9, 12, 18 and 24-months with progression,
correlations between motor function and biomarkers and hazard ratios were
analyzed.
Results
Motor function scores (MFS) and CMAP decreased rapidly in SMA
infants, whereas MFS in all healthy infants rapidly increased. Correlations
were identified between TIMPSI and CMAP in SMA infants. TIMPSI at first
study visit was associated with risk of combined endpoint of death or
permanent invasive ventilation in SMA infants. Post hoc analysis of survival
to combined endpoint in SMA infants with 2 copies of SMN2
indicated a median age of 8 months at death (95%CI: 6,17).
Interpretation
These data of SMA and control outcome measures delineates meaningful
change in clinical trials in infantile-onset SMA. The power and utility of
NeuroNEXT to provide “real world”, prospective natural
history data sets to accelerate public and private drug development programs
for rare disease is demonstrated.